Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom

Zusammenfassung

Die Behandlung der Myasthenia gravis (MG) und des Lambert-Eaton-Syndroms (LEMS) entsprechend den Leitlinien der DGN ist in der Regel sehr wirksam. Aufgrund des sehr individuellen Verlaufs beider Erkrankungen, medikamentöser Unverträglichkeiten oder schwerwiegender Begleiterkrankungen ist es allerdings nicht selten erforderlich, von den „klassischen” Immuntherapeutika (Kortikosteroide, Azathioprin) abzuweichen und andere Medikamente im Off-label-use einzusetzen, für die zwar zumeist eine schwächere Studienlage besteht, aber doch eine tragfähige klinische Evidenz gegeben ist. Der Ärztliche Beirat der Deutschen Myasthenie-Gesellschaft hat daher die verfügbaren wissenschaftlichen Daten zu diesen „Reservemedikamenten” (Methotrexat, Cyclophosphamid, Cyclosporin A, Mycophenolat Mofetil, Tacrolimus, Rituximab) hinsichtlich Indikationen und Zulassung, Studienergebnissen, praktischer Anwendung einschließlich Therapiemonitoring, unerwünschter Wirkungen und Komplikationsmöglichkeiten aktualisiert. Für jedes Medikament werden darüber hinaus Erfahrungswissen und Hinweise zur Anwendung in Schwangerschaft und Stillzeit gegeben. Diese Synopsis will therapeutische Möglichkeiten aufzeigen und Hinweise liefern, wie auch bei einem schweren Verlauf von MG oder LEMS Nutzen-Risiko-Abwägungen vorgenommen werden können. Sie können den zielgerechten Umgang mit dem unvermeidlichen Off-label-use der genannten Substanzen fördern. In einem 2. Teil wird dann auf die Therapie mit intravenösen Immunglobulinen, Plasmaaustausch und Immunadsorption eingegangen.

Abstract

The treatment of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) is – according to the guidelines of the German Neurological Society – very effective in most patients. Nevertheless due to the individual course of both diseases, adverse drug effects or severe comorbidities, it is often necessary to stop the treatment with the „classical” immunotherapeutics such as corticosteroids and azathioprine and to change to other drugs in spite of the fact that experience using them is much more scarce and that the drugs can only be given off-label. The Medical Advisory Board of the German Myasthenia Society (DMG) has therefore updated the available scientific data concerning these drugs (methotrexate, cyclophosphamide, cyclosporine, mycophenolate mofetil, tacrolimus, rituximab) with respect to indications and approval, study results, practical application and monitoring of therapy as well as adverse events and complications. Moreover, for each of these drugs, some practical information concerning pregnancy and breast-feeding is given. This publication is intended to demonstrate additional treatment modalities even in severe cases of MG or LEMS. Moreover, it may offer some arguments for the off-label-use of these drugs. In a second part of this publication, the treatment with high-dose immunoglobulins, plasma exchange and immunoadsorption will be discussed.

Myasthenia gravis - Lambert-Eaton myasthenes Syndrom - Immuntherapie - medikamentöse Immunsuppression

myasthenia gravis - Lambert-Eaton myasthenic syndrome - immunotherapy - drug-induced immunosuppression

Literatur

• 1 Fuhr P, Gold R, Toyka K V* et al. Myasthenia gravis.. In: Diener H C, Putzki N, Elger C, et al, Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie.. 4. Aufl. Stuttgart: Thieme; 2008: 686-704 (*federführend)
• 2 Schneider-Gold C, Gajdos P, Toyka K V et al. Corticosteroids for myasthenia gravis.  Cochrane Database Syst Rev. 2005;  (2) CD002828
• 3 Skeie G, Apostolski S, Evoli A et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders.  Eur J Neurol. 2010;  17 893-902
• 4 Jeffrey J A, Scala S, Royden Jones H. Ocular myasthenia gravis in a senior population. Diagnosis, therapy, and prognosis.  Muscle Nerve. 2010;  41 379-384
• 5 Schneider-Gold C, Melms A, Hohlfeld R. Myasthenia gravis und myasthene Syndrome.. In: Brandt T, Dichgans J, Diener H C, Hrsg Therapie und Verlauf neurologischer Erkrankungen.. 5. Aufl. Stuttgart: Kohlhammer; 2007: 1320-1342
• 6 Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.  Teratology. 2000;  62 385-392
• 7 Gur C, Diav-Citrin O, Shechtman S et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study.  Reprod Toxicol. 2004;  18 93-101
• 8 Pradat P, Robert-Gnansia E, Di Tanna G L et al. Contributors to the MADRE database. First trimester exposure to corticosteroids and oral clefts.  Birth Defects Res A Clin Mol Teratol. 2003;  67 968-970
• 9 Mertens H G, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents.  Eur Neurol. 1969;  2 321-339
• 10 Witte A S, Cornblath D R, Parry G J et al. Azathioprine in the treatment of myasthenia gravis.  Ann Neurol. 1984;  15 602-605
• 11 Mantegazza R, Antozzi C, Peluchetti D et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis.  J Neurol. 1988;  237 339-344
• 12 Matell G, Bergstrom K, Franksson C et al. Effects of some immunosuppressive procedures in myasthenia gravis.  Ann N Y Acad Sci. 1976;  274 659-676
• 13 Mertens H G, Hertel G, Reuther P et al. Effect of immunosuppressive drugs (azathioprine).  Ann N Y Acad Sci. 1981;  377 691-699
• 14 Kuks J BM, Djojoatmodjo S, Oosterhuis H JHG. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature.  Neuromusc Disord. 1991;  1 423-431
• 15 Sommer N, Sigg B, Melms A et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.  J Neurol Neurosurg Psychiatry. 1997;  62 156-162
• 16 Heckmann J M, LeePan E B, Eastman R W. High-dose immunosuppressive therapy in generalised myasthenia gravis – a 2-year follow-up study.  S Afr Med J. 2001;  91 765-770
• 17 Hohlfeld R, Toyka K V, Besinger U A et al. Myasthenia gravis: Reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine.  Ann Neurol. 1985;  17 238-242
• 18 Michels M, Hohlfeld R, Hartung H P et al. Myasthenia gravis: discontinuation of long-term azathioprine.  Ann Neurol. 1988;  24 798
• 19 Myasthenia Gravis Clinical Study Group . A randomised clinical trial comparing prednisolone and azathioprine in myasthenia gravis. Results of a second interim analysis.  J Neurol Neurosurg Psychiatry. 1993;  56 1157-1163
• 20 Bromberg M B, Wald J J, Forshew D A et al. Randomized trial of azathioprine or prednisolone for initial immunosuppressive treatment of myasthenia gravis.  J Neurol Sci. 1997;  150 59-62
• 21 Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis.  Neurology. 1998;  50 1778-1783
• 22 Tumani H, George A, Nau R. Myasthene Krise durch Azathioprin-induziertes Fieber.  Nervenarzt. 1997;  68 336-338
• 23 Ford L T, Berg J D. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come.  J Clin Pathol. 2010;  63 288-295
• 24 Jabin D, Kumar S, Gow P J. Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline.  N Z Med J. 2010;  123 67-73
• 25 Confavreux C, Saddier P, Grimaud J et al. Risk of cancer from azathioprine therapy in multiple sclerosis: A case control study.  Neurology. 1996;  46 1607-1612
• 26 Rawoot A, Little F, Heckmann J M. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years.  S Afr Med J. 2006;  96 1249-1251
• 27 O'Donovan P, Perrett C M, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage.  Science. 2005;  309 1871-1874
• 28 Polifka J E, Friedman J M. Teratogen update: azathioprine and 6-mercaptopurine.  Teratology. 2002;  65 240-261
• 29 Goldstein L H, Dolinsky G, Greenberg R et al. Pregnancy outcome of women exposed to azathioprine during pregnancy.  Birth Defects Res A Clin Mol Teratol. 2007;  79 696-701
• 30 Cleary B J, Källén B. Early pregnancy azathioprine use and pregnancy outcomes.  Birth Defects Res A Clin Mol Teratol. 2009;  85 647-654
• 31 Hoeltzenbein M, Weber-Schoendorfer C, Padberg S et al. Paternal exposure to azathioprine / 6-mercaptopurine – Experience of Berlin TIS.  Reprod Toxicol. 2010;  238-239 (abstract)
• 32 Francella A, Dyan A, Bodian C et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study.  Gastroenterology. 2003;  124 9-17
• 33 Zelinkova Z, De Boer I P, Van Dijke M J et al. Azathioprine treatment during lactation.  Aliment Pharmacol Ther. 2009;  30 90-91 author reply 91
• 34 Christensen L A, Dahlerup J F, Nielsen M J et al. Azathioprine treatment during lactation.  Aliment Pharmacol Ther. 2008;  28 1209-1213
• 35 Hart I K, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis.  Cochrane Database Syst Rev. 2007;  (4) CD005224
• 36 Hilton-Jones D. When the patient fails to respond to treatment: Myasthenia gravis.  Pract Neurol. 2007;  7 405-411
• 37 Tarner H J, Manger B, Fleck M et al. Evidenzbasierte Empfehlungen einer nationalen Expertenrunde zum Einsatz von Methotrexat bei entzündlich-rheumatischen Erkrankungen.  Akt Rheumatol. 2009;  34 59-66
• 38 Pagnoux C, Mahr A, Hamidou M A et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.  N Engl J Med. 2008;  359 790-803
• 39 Goodkin D E, Rudick R A, van der Brug-Medendorp S et al. Low dose (7,5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.  Ann Neurol. 1995;  37 30-40
• 40 Schneider-Gold C. Aktuelle Therapie der Myasthenia gravis und der autoimmunen Myositiden.  Akt Neurol. 2009;  36 266-269
• 41 Raja F M, Wimachkie M, McVey A L et al. Clin Neuromusc Dis. 2009;  10 abstract 136
• 42 Sathasivam S. Steroids and immunosuppressant drugs in Myasthenia gravis. Nature clinical practice.  Neurology. 2008;  4 317-327
• 43 Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis.  Neurotherapeutics. 2008;  5 535-541
• 44 Gold R, Schneider-Gold C, Toyka K V. Fortschritte in Pathogenese und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndromes.  Akt Neurol. 2008;  35 192-203
• 45 Skeie G O, Apostolski S, Evoli A et al. Guidelines for treatment of autoimmune transmission disorders.  Eur J Neurol. 2006;  13 691-699
• 46 Hilton-Jones D, Palace J. The management of myasthenia gravis.  Pract Neurol. 2005;  5 18-27
• 47 Tran H, Cheung C, Gill D et al. Methotrexate – associated mantle-cell lymphoma in an elderly man with myasthenia gravis.  Nat Clin Pract Oncol. 2008;  5 234-238
• 48 Buckley L M, Bullaboy C A, Leichtman L et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother.  Arthritis Rheum. 1997;  40 971-973
• 49 Lewden B, Vial T, Elefant E et al. French Network of Regional Pharmacovigilance Centers. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study.  J Rheumatol. 2004;  31 2360-2365
• 50 Chakravarty E F, Sanchez-Yamamoto D, Bush T M. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.  J Rheumatol. 2003;  30 241-246
• 51 Hoeltzenbein M, Weber-Schoendorfer C, von Stackelberg L et al. Paternal exposure to drugs – Is there an increased risk for congenital abnormalities? Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment during Pregnancy.  Reprod Toxicol. 2008;  26 64 (abstract)
• 52 Tindall R SA, Rollins J A, Phillips J T et al. Preliminary results of a double blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.  N Engl J Med. 1987;  316 719-724
• 53 Tindall R SA, Phillips J T, Rollins J A et al. A clinical therapeutic trial of ciclosporine in myasthenia gravis.  Ann NY Acad Sci. 1993;  681 539-551
• 54 Evoli A, Bianchi M R, Riso R et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies.  Ann NY Acad Sci. 2008;  1132 76-83
• 55 Armenti V T, Radomskir J S, Moritz M J et al. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation.  Clinical Transplants. 2005;  69-83
• 56 Bar-Oz B, Hackman R, Einarson T et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis.  Transplantation. 2001;  71 1051-1055
• 57 Moretti M E, Sgro M, Johnson D W et al. Cyclosporine excretion into breast milk.  Transplantation. 2003;  75 2144-2146
• 58 Nouza K, Smat V. The favourable effect of cyclophosphamide in myasthenia gravis.  Rev Fr Etud Clin Biol. 1968;  13 161-163
• 59 Pestronk A, Drachman D B, Adams R N. Treatment of ongoing experimental myasthenia gravis with short-term high dose cyclophosphamide.  Muscle Nerve. 1982;  5 79-84
• 60 Perez M C, Buot W L, Mercado-Danguilan C et al. Stable remission in myasthenia gravis.  Neurology. 1981;  31 32-37
• 61 Gladstone D E, Brannagan 3rd T H, Schwartzman R J et al. High dose cyclophosphamide for severe refractory myasthenia gravis.  J Neurol Neurosurg Psychiatry. 2004;  75 789-791
• 62 De Assis J L, Marchiori P E, Scaff M et al. Treatment of myasthenia gravis by immunosuppressive non-steroidal drugs.  Arq Neuropsiquiatr. 1986;  44 109-116
• 63 Niakan E, Harati Y, Rolak L A. Immunosuppressive drug therapy in myasthenia gravis.  Arch Neurol. 1986;  43 155-156
• 64 Hart I K, Sharshar T, Sathasivam S. Immunosuppressant drugs for myasthenia gravis.  J Neurol Neurosurg Psychiatry. 2009;  80 discussion 6
• 65 García-Carrasco M, Escárcega R O, Fuentes-Alexandro S et al. Therapeutic options in autoimmune myasthenia gravis.  Autoimmun Rev. 2007;  6 373-378
• 66 Spring P J, Spies J M. Myasthenia gravis: options and timing of immunomodulatory treatment.  BioDrugs. 2001;  15 173-183
• 67 Lisak R P. Myasthenia gravis.  Curr Treat Options Neurol. 1999;  1 239-250
• 68 Drachman D B, Adams R N, Hu R et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.  Ann N Y Acad Sci. 2008;  1132 305-314
• 69 Lin P T, Martin B A, Weinacker A B et al. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies.  Muscle Nerve. 2006;  33 433-435
• 70 Schumm F, Brinkmann A, Fateh-Moghadam A. Antibody-controlled cytostatic therapy of malignant thymoma with concomitant myasthenia gravis.  Dtsch Med Wochenschr. 1984;  109 1244-1246
• 71 Kosmidis P A, Iliopoulos E, Pentea S. Combination chemotherapy with cyclophosphamide, adriamycin, and vincristine in malignant thymoma and myasthenia gravis.  Cancer. 1988;  61 1736-1740
• 72 Chorzelski T, Hashimoto T, Maciejewska B et al. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans.  J Am Acad Dermatol. 1999;  41 393-400
• 73 Tomida C, Yamagata K, Ishizu T et al. A case of nephrotic syndrome associated with myasthenia gravis and malignant thymoma.  Nippon Jinzo Gakkai Shi. 1999;  41 77-82
• 74 Denayer M A, Rao K R, Wirz D et al. Hepatic metastatic thymoma and myasthenia gravis twenty-two years after the apparent cure of an invasive thymoma. A case report and review of the literature.  J Neurol Sci. 1986;  76 23-30
• 75 Flachenecker P, Taleghani B M, Gold R et al. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.  Trans Sci. 1998;  19 43-46
• 76 Zeitler H, Ulrich-Merzenich G, Hoffmann L et al. Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis.  Artif Organs. 2006;  30 597-605
• 77 Haas M, Mayr N, Zeitlhofer J et al. Long-term treatment of myasthenia gravis with immunoadsorption.  J Clin Apher. 2002;  17 84-87
• 78 Nakashima I, Kikuchi A, Onodera J et al. A juvenile case of Lambert-Eaton myasthenic syndrome with severe emaciation.  Rinsho Shinkeigaku. 1997;  37 402-406
• 79 Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome.  Cochrane Database Syst Rev. 2003;  (2) CD003279
• 80 De Feo L G, Schottlender J, Martelli N A et al. Use of intravenous cyclophosphamide in severe, generalized myasthenia gravis.  Muscle Nerve. 2002;  26 31-36
• 81 Badurska B, Ryniewicz B, Strugalska H. Immunosuppressive treatment of juvenile myasthenia gravis.  Eur J Pediatr. 1992;  151 215-217
• 82 Melms A, Hohlfeld R. Myasthenia gravis und myasthene Syndrome.. In: Brandt T, Dichgans J, Diener H-C, Hrsg Therapie und Verlauf neurologischer Erkrankungen.. Stuttgart, Berlin, Köln: Kohlhammer; 1998: 1097-1119
• 83 Diaz-Manera J, Rojas-Garcia R, Illa I. Treatment strategies for myasthenia gravis.  Expert Opin Pharmacother. 2009;  10 1329-1342
• 84 Drachman D B, Jones R J, Brodsky R A. Treatment of refractory myasthenia: „rebooting” with high-dose cyclophosphamide.  Ann Neurol. 2003;  53 7-9
• 85 Enns G M, Roeder E, Chan R T et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?.  Am J Med Genet. 1999;  86 237-241
• 86 Hahn K M, Johnson P H, Gordon N et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.  Cancer. 2006;  107 1219-1226
• 87 Ring A E, Smith I E, Jones A et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals.  J Clin Oncol. 2005;  23 4192-4197
• 88 Bargman H B, Fefferman I. Multiple dermatofibromas in a patient with myasthenia gravis treated with prednisone and cyclophosphamide.  J Am Acad Dermatol. 1986;  14 351-352
• 89 Chaudhry V, Cornblath D R, Griffin J W et al. Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases.  Neurology. 2001;  56 94-96
• 90 Ciafaloni E, Massey J M, Tucker-Lipscomb B et al. Mycophenolate mofetil for myasthenia gravis: An open-label pilot study.  Neurology. 2001;  56 97-99
• 91 Hauser R A, Malek A R, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.  Neurology. 1998;  51 912-913
• 92 Schneider C, Gold R, Reiners K et al. Mycophenolate mofetil in the therapy of severe myasthenia gravis.  Eur Neurol. 2001;  46 79-82
• 93 Meriggioli M N, Rowin J, Richman J G et al. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.  Ann NY Acad Sci. 2003;  998 494-499
• 94 Sanders D B, Hart I K, Mantegazza R et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.  Neurology. 2008;  71 400-406
• 95 The Muscle Study Group . A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.  Neurology. 2008;  71 394-399
• 96 Benatar M, Rowland L P. The muddle of mycophenolate mofetil in myasthenia.  Neurology. 2008;  71 390-391
• 97 Hehir M K, Burns T M, Alpers J et al. Mycophenolate Mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients.  Muscle Nerve. 2010;  41 593-598
• 98 Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.  Semin Neurol. 2003;  23 191-198
• 99 Anderka M T, Lin A E, Abuelo D N et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature.  Am J Med Genet A. 2009;  149A 1241-1248
• 100 Merlob P, Stahl B, Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: a review.  Reprod Toxicol. 2009;  28 105-108
• 101 Hoeltzenbein M, Elefant E, Garayt C et al. Maternal exposure to mycophenolate mofetile in pregnancy – Results of the ENTIS collaborative study.  Reprod Toxicol. 2010;  30 228 (abstract)
• 102 Yoshikawa H, Iwasa K, Satoh K et al. FK506 prevents induction of rat experimental autoimmune myasthenia gravis.  J Autoimmun. 1997;  10 11-16
• 103 Evoli A, Di Schino C, Marsili F et al. Successful treatment of myasthenia gravis with tacrolimus.  Muscle Nerve. 2002;  25 111-114
• 104 Ponseti J M, Azem J, Fort J M et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.  Neurology. 2005;  64 1641-1643
• 105 Ponseti J M, Gamez J, Azem J et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients.  Ann NY Acad Sci. 2008;  1132 254-263
• 106 Christopher V, Al-Chalabi T, Richardson P D et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients.  Liver Transpl. 2006;  12 1138-1143
• 107 Jain A B, Shapiro R, Scantlebury V P et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience.  Transplantation. 2004;  77 897-902
• 108 Gardiner S J, Begg E J. Breastfeeding during tacrolimus therapy.  Obstet Gynecol. 2006;  107 453-455
• 109 Zaja F, Russo D, Fuga G et al. Rituximab for myasthenia gravis developing after bone marrow transplant.  Neurology. 2000;  55 1062-1063
• 110 Wylam M E, Anderson P M, Kuntz N L et al. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.  J Pediatr. 2003;  143 674-677
• 111 Illa I, Diaz-Manera J, Rojas-Garcia R et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.  J Neuroimmunol. 2008;  201–202 90-94
• 112 Nelson Jr R P, Pascuzzi R M, Kessler K et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.  J Clin Neuromuscul Dis. 2009;  10 170-177
• 113 Hain B, Jordan K, Deschauer M et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.  Muscle Nerve. 2006;  33 575-580
• 114 Baek W S, Bashey A, Sheean G L. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.  J Neurol Neurosurg Psychiatry. 2007;  78 771
• 115 Pellkofer H L, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction.  Muscle Nerve. 2009;  40 305-308
• 116 Maddison P, McConville J, Farrugia M E et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.  J Neurol Neurosurg Psychiatry. 2010;  [Epub ahead of print] PubMed PMID: 20392977
• 117 Stieglbauer K, Topakian R, Schäffer V et al. Rituximab for myasthenia gravis: three case reports and review of the literature.  J Neurol Sci. 2009;  280 120-122
• 118 Zebardast N, Patwa H S, Novella S P et al. Rituximab in the management of refractory myasthenia gravis.  Muscle Nerve. 2010;  41 375-378
• 119 Klink D T, van Elburg R M, Schreurs M W et al. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development.  Clin Dev Immunol. 2008;  2008 271-363